Market Research Logo

PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024

Summary

Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.

GlobalData projects the psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-23 (IL-23) inhibitors (guselkumab and tildrakizumab), interleukin-17 (IL-17) inhibitors (Cosentyx, Taltz, and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developments of biosimilars , are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.

Highlights

Key Questions Answered

  • How good is the management of Psoriasis with marketed therapies?
  • Which drugs and players are important in the current management landscape?
  • What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the Psoriasis market?
  • What are the significant unmet needs and remaining opportunities in the Psoriasis market?
  • What clinical and commercial factors are likely to uptake of Psoriasis therapies in the US, 5EU, Japan and India?
Key Findings
  • The psoriasis market is currently very dynamic, with effective biologic therapies awaiting approval, such as interleukin-17 (IL-17) inhibitor- brodalumab, interleukin-23 (IL-23) inhibitors- guselkumab and tildrakizumab.
  • Novel biologic therapies will challenge the current anti-TNF biologics in an attempt to dislodge their stronghold, if their safety and efficacy profiles are proven once they enter the market.
  • The impending patent cliff for biologics will allow for the emergence of biosimilars to all the marketed biologic brands. Patent expiries take place during the forecast period for the current market leaders such as Johnson & Johnson’s Remicade (infliximab), AbbVie’s Humira (adalimumab), Amgen’s Enbrel (etanercept) and Johnson & Johnson’s Stelara (ustekinumab).
  • The drivers for market growth will also include affordable treatments throughout the world, as well as the push for long-term drug efficacy. The main challenge for individual drugs will be to distinguish themselves in a crowded marketplace, comprising a highly diversified field of therapies, with existing drugs struggling to increase their patient share.
Scope
  • Overview of Psoriasis, including epidemiology, etiology, pathophysiology, symptoms and current treatment options
  • Topline Psoriasis market revenue from 2014-2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include strategic competitor assessment, unmet needs, pipeline assessment, and market outlook for the Psoriasis market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products- including promising IL-17 and IL-23 inhibitors.
  • Analysis of the current and future market competition in the global Psoriasis market (8MM). Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Psoriasis market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Psoriasis market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.3.1 Prevalence
4.4 Forecast Methodology
4.4.1 Sources Used for One-Year Diagnosed Prevalence of Psoriasis
4.4.2 Sources Not Used
4.4.3 Forecast Assumptions and Methods, One-Year Diagnosed Prevalent Cases of Psoriasis
4.5 Epidemiological Forecast for Psoriasis (2014-2024)
4.5.1 One-Year Diagnosed Prevalent Cases of Psoriasis
4.5.2 Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis
4.5.3 Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis
4.5.4 Age-Standardized One-Year Diagnosed Prevalent Cases of Psoriasis
4.5.5 One-Year Diagnosed Prevalent Cases of Psoriasis by Severity
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.1.1 Diagnosis
5.1.2 Leading Prescribed Drugs and Treatment Guidelines
5.1.3 Clinical Practice
5.2 US
5.3 5EU
5.4 Japan
5.5 India
6 Competitive Assessment
6.1 Overview
6.2 Strategic Competitor Assessment
6.3 Product Profiles - Major Brands
6.3.1 Enbrel (Etanercept)
6.3.2 Humira (Adalimumab)
6.3.3 Remicade (Infliximab)
6.3.4 Stelara (Ustekinumab)
6.3.5 Cosentyx (Secukinumab)
6.3.6 Taltz (Ixekizumab)
6.3.7 Otezla (Apremilast)
6.3.8 Taclonex and Enstilar (Calcipotriene and Betamethasone Dipropionate)
6.3.9 Methotrexate
6.3.10 Fumaderm (Fumaric Acid Esters)
6.3.11 Alzumab (Itolizumab)
6.3.12 Other Therapeutic Drug Classes Used in Psoriasis
6.3.13 Non-pharmacological Therapy
7 Unmet Need and Opportunity
7.1 Overview
7.2 Limited Patient Access Due to Drug Reimbursement Pattern
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Improved Drug Safety and Efficacy Profiles
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 Education and Treatment of Psychological Factors Accompanying Psoriasis
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
8 Pipeline Assessment
8.1 Overview
8.2 Clinical Trial Mapping
8.2.1 Clinical Trials by Country
8.3 Clinical Trials by Phase and Trial Status
8.4 Promising Drugs in Clinical Development
8.4.1 Xeljanz (Tofacitinib)
8.4.2 Brodalumab
8.4.3 Guselkumab (CNTO-1959)
8.4.4 Tildrakizumab
8.4.5 Piclidenoson (CF-101)
8.4.6 Additional Phase III Pipeline Products
8.4.7 Phase II Pipeline Products
8.4.8 Phase I Pipeline Products
8.5 Biosimilar Pipeline Products
8.5.1 Introduction
8.5.2 Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases
8.5.3 Biosimilars in the Immunology Community
8.5.4 By the Numbers: Biosimilars in Development
8.5.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
8.5.6 Uptake of Biosimilars for Psoriasis is Expected to Vary by Market
8.5.7 Biosimilars Forecast
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
9.3.1 Johnson & Johnson
9.3.2 AbbVie
9.3.3 Amgen
9.3.4 Novartis
9.3.5 Pfizer
9.3.6 Eli Lilly
9.3.7 Merck
9.3.8 LEO Pharma
9.3.9 Celgene
9.3.10 Can-Fite Biopharma
10 Market Outlook
10.1 Global Markets
10.1.1 Forecast
10.1.2 Drivers and Barriers - Global Issues
10.2 US
10.2.1 Forecast
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3 5EU
10.3.1 Forecast
10.3.2 Key Events
10.3.3 Drivers and Barriers
10.4 Japan
10.4.1 Forecast
10.4.2 Key Events
10.4.3 Drivers and Barriers
10.5 India
10.5.1 Forecast
10.5.2 Key Events
10.5.3 Drivers and Barriers
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Diagnosed Psoriasis Patients
11.4.2 Percent Drug-Treated Patients
11.4.3 Drugs Included in Each Therapeutic Class
11.4.4 Launch and Patent Expiry Dates
11.4.5 General Pricing Assumptions
11.4.6 Individual Drug Assumptions
11.4.7 Generic Erosion
11.4.8 Pricing of Pipeline agents
11.5 Physicians and Specialists Included in this Study
11.6 Primary Research - Prescriber Survey
11.7 About the Authors
11.7.1 Author
11.7.2 Reviewer
11.7.3 Epidemiologist
11.7.4 Global Director of Therapy Analysis and Epidemiology
11.7.5 Global Head of Healthcare
11.8 About GlobalData
11.9 Disclaimer
1.1 List of Tables
Table 1: Immune Cells Involved in Lesions
Table 2: Symptoms of Psoriasis
Table 3: Risk Factors and Comorbidities for Psoriasis
Table 4: 8MM, Global Trends for the Diagnosed Prevalence of Psoriasis
Table 5: 8MM, Sources of Epidemiological Data Used for the Forecast for Psoriasis One-Year Diagnosed Prevalent Cases
Table 6: 8MM, Sources of Epidemiological Data Used for the Segmentation of One-Year Diagnosed Prevalent Cases of Psoriasis by Severity
Table 7: 8MM, One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, All Ages, N, 2014-2024
Table 8: 8MM, Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, N (Row %), 2014
Table 9: 8MM, Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, All Ages, N (Row %), 2014
Table 10: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis
Table 11: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2014
Table 12: Treatment Guidelines for Psoriasis
Table 13: Country Profile - US
Table 14: Country Profile - 5EU
Table 15: Country Profile - Japan
Table 16: Country Profile - India
Table 17: Leading Treatments for Psoriasis, 2015
Table 18: Product Profile - Enbrel
Table 19: Enbrel Pivotal Study I Outcomes at 3 and 6 Months
Table 20: Enbrel pivotal study II outcomes at 3 Months
Table 21: Long-Term Studies on Enbrel Efficacy in Treatment of Psoriasis
Table 22: Long-Term Safety Profile of Enbrel in the Treatment of Psoriasis
Table 23: Enbrel SWOT Analysis, 2015
Table 24: Global Sales Forecast ($m) for Enbrel, 2014-2024
Table 25: Product Profile - Humira
Table 26: Humira pivotal study outcomes at 16 weeks
Table 27: Humira SWOT Analysis, 2015
Table 28: Global Sales Forecast ($m) for Humira, 2014-2024
Table 29: Product Profile - Remicade
Table 30: Efficacy Results of RESTORE1 Trial of Remicade vs. MTX at Week 26
Table 31: Safety Results and AEs of RESTORE1 Trial of Remicade vs. MTX at Week 16
Table 32: Remicade SWOT Analysis, 2015
Table 33: Global Sales Forecast ($m) for Remicade, 2014-2024
Table 34: Product Profile - Stelara
Table 35: Stelara Pivotal Study Outcomes at Week 12
Table 36: Stelara SWOT Analysis, 2015
Table 37: Global Sales Forecast ($m) for Stelara, 2014-2024
Table 38: Product Profile - Cosentyx
Table 39: Efficacy Endpoints in Cosentyx Phase III ERASURE Study
Table 40: Efficacy End Points in Cosentyx Phase III FIXTURE study
Table 41: Cosentyx SWOT Analysis, 2015
Table 42: Global Sales Forecast ($m) for Cosentyx, 2014-2024
Table 43: Product Profile - Taltz
Table 44: Efficacy Results of UNCOVER-2 at Week 12
Table 45: Efficacy Results of UNCOVER-3 at Week 12
Table 46: Taltz SWOT Analysis, 2015
Table 47: Global Sales Forecast ($m) for Taltz, 2014-2024
Table 48: Product Profile - Otezla
Table 49: Otezla Efficacy Results at Week 16 in Studies ESTEEM-1 and ESTEEM-2
Table 50: Otezla SWOT Analysis, 2015
Table 51: Global Sales Forecast ($m) for Otezla, 2014-2024
Table 52: Product Profile - Taclonex/Enstilar
Table 53: Taclonex Efficacy Outcomes from Pivotal Phase III Studies for Adult Scalp and Body Psoriasis.
Table 54: Taclonex/Enstilar SWOT Analysis, 2015
Table 55: Global Sales Forecast ($m) for Taclonex/Daivobet/Dovobet, 2014-2024
Table 56: Product Profile - Methotrexate
Table 57: Methotrexate SWOT Analysis, 2015
Table 58: Global Sales Forecast ($m) for Methotrexate, 2014-2024
Table 59: Product Profile - Fumaderm
Table 60: Fumaderm SWOT Analysis, 2015
Table 61: Global Sales Forecast ($m) for Fumaderm, 2014-2024
Table 62: Product Profile - Alzumab
Table 63: Alzumab SWOT Analysis, 2013
Table 64: Global Sales Forecast ($m) for Alzumab, 2014-2024
Table 65: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2015
Table 66: Dosing Guidelines for Broadband Ultraviolet B
Table 67: Dosing Guidelines for Narrowband Ultraviolet B
Table 68: Overall Unmet Needs in Psoriasis - Current Level of Attainment
Table 69: Psoriasis - Clinical Trials by Phase and Status, 2015
Table 70: Psoriasis - Phase Pipeline, 2015
Table 71: Comparison of Therapeutic Classes in Development for Psoriasis, 2015
Table 72: Product Profile - Xeljanz
Table 73: Xeljanz SWOT Analysis, 2015
Table 74: Global Sales Forecast ($m) for Xeljanz, 2014-2024
Table 75: Product Profile - Brodalumab
Table 76: Brodalumab SWOT Analysis, 2015
Table 77: Global Sales Forecast ($m) for Brodalumab, 2014-2024
Table 78: Product Profile - Guselkumab
Table 79: Guselkumab SWOT Analysis, 2015
Table 80: Global Sales Forecast ($m) for Guselkumab, 2014-2024
Table 81: Product Profile - Tildrakizumab
Table 82: Tildrakizumab SWOT Analysis, 2015
Table 83: Global Sales Forecast ($m) for Tildrakizumab, 2014-2024
Table 84: Product Profile - Piclidenoson (CF-101)
Table 85: Piclidenoson SWOT Analysis, 2015
Table 86: Additional Phase III Psoriasis Pipeline drugs, 2015
Table 87: Phase II Psoriasis Pipeline, 2015
Table 88: Phase I Psoriasis Pipeline, 2015
Table 89: Marketed and Pipeline Biosimilars for Psoriasis in the 8MM, 2015
Table 90: Physician Uptake of Biosimilar Products for Psoriasis Across the 8MM, 2015
Table 91: Global Sales Forecast ($m) for Etanercept Biosimilars, 2014-2024
Table 92: Global Sales Forecast ($m) for Adalimumab Biosimilars, 2014-2024
Table 93: Global Sales Forecast ($m) for Infliximab Biosimilars, 2014-2024
Table 94: Key Companies in the Psoriasis Market, 2015
Table 95: J&J’s Psoriasis Portfolio Assessment, 2015
Table 96: J&J’s Psoriasis Portfolio SWOT Analysis, 2015
Table 97: AbbVie’s Psoriasis Portfolio Assessment, 2015
Table 98: AbbVie’s Psoriasis SWOT Analysis, 2015
Table 99: Amgen’s Psoriasis Portfolio Assessment, 2015
Table 100: Amgen’s Psoriasis SWOT Analysis, 2015
Table 101: Novartis’s Psoriasis Portfolio Assessment, 2015
Table 102: Novartis’ Psoriasis SWOT Analysis, 2015
Table 103: Pfizer’s Psoriasis Portfolio Assessment, 2015
Table 104: Pfizer’s Psoriasis Portfolio SWOT Analysis, 2015
Table 105: Eli Lilly’s Psoriasis Portfolio Assessment, 2015
Table 106: Eli Lilly’s Psoriasis Portfolio SWOT Analysis, 2015
Table 107: Merck’s Psoriasis Portfolio Assessment, 2015
Table 108: Merck’s Psoriasis Portfolio SWOT Analysis, 2015
Table 109: LEO Pharma’s Psoriasis Portfolio Assessment, 2015
Table 110: LEO Pharma’s Psoriasis Portfolio SWOT Analysis, 2015
Table 111: Celgene’s Psoriasis Portfolio Assessment, 2015
Table 112: Celgene’s Psoriasis Portfolio SWOT Analysis, 2015
Table 113: Can-Fite’s Psoriasis Portfolio Assessment, 2015
Table 114: Celgene’s Psoriasis Portfolio SWOT Analysis, 2015
Table 115: Global Sales Forecast ($m) for Psoriasis, 2014-2024
Table 116: Global Psoriasis Market - Drivers and Barriers, 2014-2024
Table 117: Sales Forecast ($) for Psoriasis in the US, 2014-2024
Table 118: Key Events Impacting Sales for Psoriasis in the US, 2014-2024
Table 119: Psoriasis Market in the US - Drivers and Barriers, 2014-2024
Table 120: Sales Forecast ($) for Psoriasis in the 5EU, 2014-2024
Table 121: Key Events Impacting Sales for Psoriasis in the 5EU, 2014-2024
Table 122: Psoriasis Market in the 5EU - Drivers and Barriers, 2014-2024
Table 123: Sales Forecast ($) for Psoriasis in Japan, 2014-2024
Table 124: Key Events Impacting Sales for Psoriasis in Japan, 2014-2024
Table 125: Psoriasis Market in Japan - Drivers and Barriers, 2014-2024
Table 126: Sales Forecast ($) for Psoriasis in India, 2014-2024
Table 127: Key Events Impacting Sales for Psoriasis in India, 2014-2024
Table 128: Psoriasis Market in India - Drivers and Barriers, 2014-2024
Table 129: Key Launch Dates
Table 130: Key Patent Expiries
Table 131: Key Launch Dates
Table 132: Physicians Surveyed, by Country
1.2 List of Figures
Figure 1: Psoriatic Plaque on Elbow of Patient
Figure 2: The Three Layers of the Skin and Associated Structures
Figure 3: Healthy Skin Versus Psoriatic Skin
Figure 4: 8MM, One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, All Ages, N, 2014-2024
Figure 5: 8MM, Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, N, 2014
Figure 6: 8MM, Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, All Ages, N, 2014
Figure 7: 8MM, Age-Standardized One-Year Diagnosed Prevalent Cases of Psoriasis (%), All Ages, by Sex, 2014
Figure 8: 8MM, Severity Profile of One-Year Diagnosed Prevalent Cases of Psoriasis, All Ages, Both Sexes, N, 2014
Figure 9: Psoriasis Therapeutics - Ongoing Clinical Trial Sites by Country, 2015
Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, 2014-2024
Figure 11: Biosimilar Prescribing Habits in Psoriasis Across the 8MM, 2015
Figure 12: Global Sales Forecast ($m) for Enbrel vs. Etanercept Biosimilars, 2014-2024
Figure 13: Global Sales Forecast ($m) for Humira vs. Adalimumab Biosimilars, 2014-2024
Figure 14: Global Sales Forecast ($m) for Remicade vs. Infliximab Biosimilars, 2014-2024
Figure 15: Company Portfolio Gap Analysis in Psoriasis, 2014-2024
Figure 16: Global Sales for Psoriasis by Region, 2014-2024
Figure 17: Sales for Psoriasis in the US by Drug Class, 2014-2024
Figure 18: Sales for Psoriasis in the 5EU by Drug Class, 2014-2024
Figure 19: Sales for Psoriasis in the 5EU by Region, 2014-2024
Figure 20: Sales for Psoriasis in Japan by Drug Class, 2014-2024
Figure 21: Sales for Psoriasis in India by Drug Class, 2014-2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report